Precision BioSciences (DTIL) Q4 2025 earnings summary

Executive summary

• Achieved key clinical milestones in 2025, including Phase 1 data for PBGENE-HBV and IND clearance for PBGENE-DMD.

• Raised $75 million in November 2025, extending cash runway through 2028.

• Presented first molecular evidence of viral DNA gene editing in patients with chronic hepatitis B.

• Partnered programs and non-core assets generated milestone payments and expanded clinical activity.

Financial highlights

• Q4 2025 revenue was $34.2 million, up from $0.6 million in Q4 2024, mainly due to Novartis and Imugene agreements.

• Q4 2025 net income was $20.1 million ($1.06 per share basic), compared to a net loss of $17.8 million in Q4 2024.

• FY 2025 revenue was $34.3 million, down from $68.7 million in FY 2024, reflecting the conclusion of prior collaborations.

• FY 2025 net loss was $45.7 million ($3.56 per share), compared to net income of $7.2 million in FY 2024.

• Cash and equivalents totaled $137.2 million as of December 31, 2025.

Outlook and guidance

• PBGENE-HBV: Additional clinical data expected in 2026; dosing in key cohorts to inform expansion phase.

• PBGENE-DMD: Initial patient data anticipated by year-end 2026; trial site activation underway.

• Cash runway expected to fund operations and milestones through 2028.